AOU Città della Salute e della Scienza di Torino – PO Molinette

Titolo:	Observational Study in Adult Patients with Chronic Myeloid Leukemia who discontinue Tyrosine Kinase Inhibitors in Italy
Patologia:	CML
Tipo di Studio:	registro
Fase:	osservazionale
Principali criteri di inclusione:	Age > 18 - Patients with CP-CML, treated with TKI monotherapy or TKI in association with other drugs (such as interferon, BCR-ABL1 peptidic vaccine and others) - Treatment with TKI discontinued for any reason - Deep Molecular Response (DMR), defined as MR4 (BCR-ABL1 ratio ≤ 0.01% with at least 10,000 ABL1 copies), or MR4.5 (BCR-ABL1 ratio ≤ 0.0032% with at least 32,000 ABL1 copies), or MR5 (BCR-ABL1 ratio ≤ 0.001% with at least 100,000 ABL1 copies), confirmed at least three times before TKI discontinuation. In patients who dis□continued TKIs before the establishment of molecular standardization, DMR will be de□fined as a level of BCR-ABL1 transcript undetectable by qPCR or by qualitative PCR, confirmed in at least two controls. - Participant is willing and able to give informed consent for participation in the study Data regarding patients discontinuing in less than DMR (as defined above) will be collec□ted and analysed separately
Principali criteri di esclusione:	Patients who were diagnosed with accelerated or blastic phase CML will be excluded
Sede e contatti	SC Ematologia U AOU Città dellla Salute e della Scienza di Torino Via Genova 3, 10126 TO Eloise Beggiato ebeggiato@cittadellasalute.to.it 0116334279